Atlas Trials

Sequential Chemotherapy With Befotertinib in Non-Small Cell Lung Cancer (NSCLC) Patients With Resistance to Third-Generation EGFR-TKI

Clinical trial NCT07181499 · RECRUITING

Trial details

NCT number
NCT07181499
Sponsor
Betta Pharmaceuticals Co., Ltd.
Status
RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
NSCLCAdjuvant Drug TherapyEGFR
Start date
2025-09-01
Primary completion
2028-11-01
Enrollment
28

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.